CN1289495C - 新的哌啶基－烷基氨基－哒嗪酮衍生物、其制备方法以及包含所述化合物的药物组合物 - Google Patents

新的哌啶基－烷基氨基－哒嗪酮衍生物、其制备方法以及包含所述化合物的药物组合物 Download PDF

Info

Publication number
CN1289495C
CN1289495C CNB028288165A CN02828816A CN1289495C CN 1289495 C CN1289495 C CN 1289495C CN B028288165 A CNB028288165 A CN B028288165A CN 02828816 A CN02828816 A CN 02828816A CN 1289495 C CN1289495 C CN 1289495C
Authority
CN
China
Prior art keywords
general formula
alkylamino
piperidyl
acid salt
pharmaceutically useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028288165A
Other languages
English (en)
Chinese (zh)
Other versions
CN1630652A (zh
Inventor
J·巴克茨
I·加克萨里
L·G·哈辛
P·科泰纳吉
G·勒维
E·施密特
G·斯米格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egyt Gyogyszervegyeszeti Gyar
Egis Pharmaceuticals PLC
Original Assignee
Egis Pharmaceuticals PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Pharmaceuticals PLC filed Critical Egis Pharmaceuticals PLC
Publication of CN1630652A publication Critical patent/CN1630652A/zh
Application granted granted Critical
Publication of CN1289495C publication Critical patent/CN1289495C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CNB028288165A 2002-04-26 2002-12-28 新的哌啶基－烷基氨基－哒嗪酮衍生物、其制备方法以及包含所述化合物的药物组合物 Expired - Fee Related CN1289495C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP0201374 2002-04-26
HU0201374A HU227255B1 (en) 2002-04-26 2002-04-26 Novel piperidine-alkyl-amino-pyridazine derivatives, pharmaceutical compositions containing the same and process for the preparation of the active ingredient

Publications (2)

Publication Number Publication Date
CN1630652A CN1630652A (zh) 2005-06-22
CN1289495C true CN1289495C (zh) 2006-12-13

Family

ID=89980388

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028288165A Expired - Fee Related CN1289495C (zh) 2002-04-26 2002-12-28 新的哌啶基－烷基氨基－哒嗪酮衍生物、其制备方法以及包含所述化合物的药物组合物

Country Status (24)

Country Link
US (1) US7183283B2 (enExample)
EP (1) EP1501823B1 (enExample)
JP (1) JP2005526113A (enExample)
KR (1) KR20040104608A (enExample)
CN (1) CN1289495C (enExample)
AT (1) ATE312091T1 (enExample)
AU (1) AU2002356351A1 (enExample)
BR (1) BR0215672A (enExample)
CA (1) CA2480293A1 (enExample)
CY (1) CY1105422T1 (enExample)
CZ (1) CZ20041085A3 (enExample)
DE (1) DE60207895T2 (enExample)
DK (1) DK1501823T3 (enExample)
EA (1) EA007202B1 (enExample)
ES (1) ES2254793T3 (enExample)
HU (1) HU227255B1 (enExample)
MX (1) MXPA04010411A (enExample)
NO (1) NO20045124L (enExample)
NZ (1) NZ536639A (enExample)
PL (1) PL371520A1 (enExample)
SI (1) SI1501823T1 (enExample)
SK (1) SK50162004A3 (enExample)
WO (1) WO2003091244A1 (enExample)
ZA (1) ZA200408849B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004010207A1 (de) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
HUP0600555A3 (en) * 2006-07-03 2008-10-28 Egis Gyogyszergyar Nyrt Use of 4-chloro-5-{2-[4-(6-fluoro-1,2-benz[d]izoxazol-3-yl)piperidin-1-yl]ethylamino}2-methyl-3(2h)-piridazinon for the production of pharmaceutical compositions for influencing cognitive functions and causing neuroprotective effect
US20100211495A1 (en) * 2009-02-13 2010-08-19 Bank Of America Corporation Systems, methods and computer program products for improving foreign currency exchange in a comprehensive payment hub system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225955B1 (en) * 2001-07-26 2008-01-28 Egis Gyogyszergyar Nyilvanosan Novel 2h-pyridazin-3-one derivatives, process for their preparation, their use and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EA007202B1 (ru) 2006-08-25
EP1501823B1 (en) 2005-12-07
HK1075656A1 (en) 2005-12-23
ZA200408849B (en) 2006-09-27
EA200401417A1 (ru) 2005-04-28
WO2003091244A1 (en) 2003-11-06
HU0201374D0 (enExample) 2002-06-29
EP1501823A1 (en) 2005-02-02
BR0215672A (pt) 2005-02-01
CA2480293A1 (en) 2003-11-06
ES2254793T3 (es) 2006-06-16
JP2005526113A (ja) 2005-09-02
AU2002356351A1 (en) 2003-11-10
PL371520A1 (en) 2005-06-27
CY1105422T1 (el) 2010-04-28
DK1501823T3 (da) 2006-04-10
CN1630652A (zh) 2005-06-22
SK50162004A3 (sk) 2005-06-02
SI1501823T1 (sl) 2006-06-30
DE60207895D1 (de) 2006-01-12
ATE312091T1 (de) 2005-12-15
US7183283B2 (en) 2007-02-27
MXPA04010411A (es) 2005-02-17
US20050215560A1 (en) 2005-09-29
NO20045124L (no) 2004-11-24
HU227255B1 (en) 2010-12-28
KR20040104608A (ko) 2004-12-10
DE60207895T2 (de) 2006-08-10
NZ536639A (en) 2006-09-29
CZ20041085A3 (cs) 2005-10-12
HUP0201374A2 (hu) 2005-01-28

Similar Documents

Publication Publication Date Title
CN1129597C (zh) 杂环化合物和以其为有效成分的抗肿瘤剂
CN1247571C (zh) 新颖的2h－哒嗪－3－酮衍生物、含有它们的药物组合物和活性成分的制备方法
CN1210268C (zh) ((环)烷基取代的)－γ－氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途
CN1281606C (zh) 含氮杂环化合物
CN1015057B (zh) 哌嗪基-杂环化合物的制备方法
CN1015707B (zh) 酰胺衍生物的生产方法
CN1044094A (zh) α-氨基嘧啶酮衍生物
CN1195741C (zh) 嘧啶酮化合物,包含该化合物的药物组合物以及制备该化合物的方法
CN1006792B (zh) 羟基、烷氧基和苯氧嘧啶类的制备方法
CN101048157A (zh) 代谢型谷氨酸受体的杂环二氢茚酮增强剂
IL235097A (en) History of insulin-2 and as protein kinase inhibitors
CN1711249A (zh) 可用作抗痛觉过敏剂的喹唑啉酮衍生物
CN1305465A (zh) 芳基链烷酰基哒嗪化合物
CN101048384A (zh) 促代谢型谷氨酸盐受体的嘧啶和喹啉增效剂
CN1440398A (zh) 用作抗惊厥药的取代2－苯并[c]呋喃酮
CN1166623C (zh) 2-苯氧基苯胺类衍生物
CN1069491A (zh) 2-(哌啶-1-基)乙醇衍生物，其制法及其治疗应用
CN1234799A (zh) 1,4－二取代的哌嗪
CN1289495C (zh) 新的哌啶基－烷基氨基－哒嗪酮衍生物、其制备方法以及包含所述化合物的药物组合物
CN1956962A (zh) 四氢异喹啉磺酰胺衍生物，其制备方法及其在治疗中的应用
CN1046517C (zh) 三唑并哒嗪,其制备和应用
CN1069022A (zh) 用于治疗肥胖及相关状态的4-[2-(2-羟基-2-苯乙氨基)乙氧基]苯乙酸衍生物
CN1742004A (zh) 具有止痛活性的吲唑酰胺类
CN1185214C (zh) 新的茚并吲哚酮化合物,其制备方法和含有这种化合物的药物组合物
CN1558904A (zh) 取代的烷基氨基哒嗪酮衍生物、其制备方法和含有这种衍生物的药用组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee